SciELO - Scientific Electronic Library Online

 
vol.31 issue9Bladder urothelial carcinoma stage T1: Substaging, invasion morphological patterns and its prognosis significancePrognosis and predictive factors of prostate cancer in the prostatic biopsy author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Actas Urológicas Españolas

Print version ISSN 0210-4806

Abstract

MOLINIE, V.  and  BAUMERT, H.. New markers in prostate biopsies. Actas Urol Esp [online]. 2007, vol.31, n.9, pp.1009-1024. ISSN 0210-4806.

The use of serum prostate-specific antigen screening to facilitate early detection of prostate cancer has resulted in a dramatic increase in the number of prostate needle core biopsies which pathologists must examine. This has been accompanied by a strong increase in the number of biopsies with ambiguous lesions, and an unequivocal diagnosis of malignancy is difficult to render, especially in the case of limited foci or in small atypical acinar lesions. When assessing small foci of atypical glands upon needle biopsy, the pathologist searches for differences between the benign glands and atypical glands in terms of usual morphological features and in such cases, immunohistochemical stains for basal cell markers such as 34ßE12 antibody or antibodies directed against cytokeratin 5 and 6 and more recently p63 may be a useful adjuvant to identify basal cells which are typically present in benign glands but absent in prostatic carcinoma. However several benign mimickers of prostate carcinoma, including atrophy, atypical adenomatous hyperplasia, nephrogenic adenoma can stain negatively with these antibodies and thus a negative basal cell marker immunostain alone does not exclude a diagnosis of benignancy. Alphamethyl-coenzyme-A-racemase (AMACR) a new sensitive marker of prostate carcinoma, can be useful in confirming ambiguous lesion suspected for malignancy. Although, as with any immunohistochemical studies, problems exist in terms of both sensitivity and specificity. The aim of this review is to describe the histological features of prostatic carcinoma in case of small focus, and discuss the application of these new prostatic markers in the light of the current literature to highlight the best practice guidelines.

Keywords : Prostate cancer; AMACR/p504s; Racemase; Minimal prostate cancer; ASAP; Immunostaining; p63.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License